12:00 AM
Mar 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Droxidopa: Phase II data

In a double-blind, placebo-controlled, U.S. Phase II trial in 85 patients, droxidopa did not meet the primary endpoint of a significant improvement in mean arterial blood pressure (BP) during dialysis, as recorded every 20 minutes. Compared with a 1.6 mmHg mean increase in patients receiving placebo, patients receiving 600 mg droxidopa had a mean increase of 1.95 mmHg, while those receiving 400 mg droxidopa had a mean decrease...

Read the full 318 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >